These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33456654)

  • 1. Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.
    Hardy YO; Hutton-Mensah KA; Amenuke DAY; Amoah-Dankwah J
    Pan Afr Med J; 2020; 37(Suppl 1):30. PubMed ID: 33456654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.
    Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C
    Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
    Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
    J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
    Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
    JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
    Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
    J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.
    Vaidya G; Czer LSC; Kobashigawa J; Kittleson M; Patel J; Chang D; Kransdorf E; Shikhare A; Tran H; Vo A; Ammerman N; Huang E; Zabner R; Jordan S
    Transplant Proc; 2020 Nov; 52(9):2711-2714. PubMed ID: 32563584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy.
    Masci GM; Iafrate F; Ciccarelli F; Pambianchi G; Panebianco V; Pasculli P; Ciardi MR; Mastroianni CM; Ricci P; Catalano C; Francone M
    Radiol Med; 2021 Sep; 126(9):1170-1180. PubMed ID: 34089436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol AK; Weiss A; Danahey K; Karrison TG; Edens CC; Bauer Ventura I; Pettit NN; Patel BK; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    Clin Pharmacol Ther; 2021 Mar; 109(3):688-696. PubMed ID: 33210302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.
    Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J
    QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.